Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Colorectal Neoplasms 50Stomach Neoplasms 13Colonic Neoplasms 5Rectal Neoplasms 4Sarcoma 3Neoplasms 2Neoplasm Metastasis 2Esophageal Squamous Cell Carcinoma 2Carcinoma, Hepatocellular 2Advanced Colorectal Carcinoma 2Unresectable Metastatic Colorectal Cancer 1To Evaluate the Efficacy of Fruquintinib and Pirfenidone in Combination With Anti-PD-1 Antibody in Colorectal Carcinoma 1TAS 102 1Sarcoma, Ewing 1Platinum Resistant Ovarian Cancer 1Patients With Advanced Metastatic Colorectal Cancer 1Pancreatic Neoplasms 1Osteosarcoma 1Neoplasm, Residual 1Metastatic Colorectal Adenocarcinoma 1Metastasis Colorectal Cancer 1Locally Advanced Rectal Cancer 1HER2-positive Gastric Cancer 1Gastric Cancer Adenocarcinoma Metastatic 1Fruquintinib 1Esophageal Neoplasms 1Endometrial Neoplasms 1Colorectal Cancer Metastatic 1Colorectal Adenocarcinoma 1Carcinoma, Renal Cell 1

Interventions

zolbetuximab 1trifluridine tipiracil drug combination 1tipiracil 1camrelizumab 1Trifluridine 1Taxes 1HMPL-013 1Bevacizumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
OTHER × Gastric Cancer Adenocarcinoma Metastatic × HMPL-013 × Clear all
NCT07392346 2026-02-11

Safety and Efficacy of Fruquintinib Plus Nab-Paclitaxel and Iparomlimab and Tuvonralimab Injection in the Second-Line Treatment for Immunotherapy-experienced Advanced Gastric Cancer

Chinese PLA General Hospital

Phase 2 Recruiting
68 enrolled
Gastrointestinal

Gastric Cancer Adenocarcinoma Metastatic

Data powered by HemOnc (CC BY 4.0) Colophon âš¡